echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NEJM: BNT162b2 and mRNA-1273 vaccines prevent new coronary pneumonia from real-world research data

    NEJM: BNT162b2 and mRNA-1273 vaccines prevent new coronary pneumonia from real-world research data

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In the phase III clinical study, the two RNA vaccines BNT162b2 and mRNA-1273 showed good preventive effects against new coronary pneumonia .
    After the vaccine has been vaccinated in a large area, the effectiveness of these two vaccines in preventing symptomatic and asymptomatic new coronary pneumonia infection in real conditions is comparable to that of clinical trials .
    Recently, researchers examined the effects of two RNA vaccines in the real world on reducing the risk of symptoms after infection, reducing viral load, and shortening the time for positive tests .

    New coronary pneumonia infection prevention recently researchers have investigated the effects of two RNA vaccines in the real world on reducing the risk of symptoms after infection, reducing the viral load and shortening the time to test positive.


    Recently, researchers have investigated the effects of two RNA vaccines in the real world.
    The effect of reducing the risk of symptoms after infection, reducing the viral load and shortening the time to test positive

    This prospective cohort study included 3975 healthy participants.


    From December 14, 2020 to April 10, 2021, participants will undergo weekly nasal swab nucleic acid tests to evaluate the preventive effect of the vaccine


    During the study period, 204 participants tested positive for nucleic acid (5%), of which 5 completed the vaccination (2 doses of vaccination over 14 days), and 11 partially completed the vaccination (14 days after the completion of the first vaccination, but the second Less than 14 days after the first vaccination), 156 people were not vaccinated
    .


    After completing the vaccination, the effective rate of the vaccine was 91%, and 81% after completing the partial vaccination


    After completing the vaccination, the effective rate of the vaccine was 91%, and 81% after completing the partial vaccination


    Real-world studies have shown that BNT162b2 and mRNA-1273, these two RNA vaccines, are effective in preventing new coronary pneumonia.


    BNT162b2 and mRNA-1273, these two RNA vaccines are effective in preventing new coronary pneumonia.


    Original source:

    Mark G.


    Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.